Arbutus Biopharma Corporation
ABUS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $22 | $37 | $37 | $36 |
| Short-Term Investments | $71 | $61 | $76 | $86 |
| Receivables | $1 | $1 | $1 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $4 | $3 | $2 |
| Total Curr. Assets | $97 | $103 | $117 | $127 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $4 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $98 | $103 | $117 | $132 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $2 | $2 |
| Short-Term Debt | $1 | $1 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $7 | $8 |
| Other Curr. Liab. | $4 | $3 | $10 | $5 |
| Total Curr. Liab. | $5 | $5 | $19 | $16 |
| LT Debt | $0 | $1 | $1 | $1 |
| Deferred Rev, NC | $0 | $0 | $3 | $3 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $15 | $15 | $15 | $15 |
| Total NC Liab. | $15 | $15 | $18 | $19 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $1 | $1 |
| Total Liabilities | $20 | $20 | $38 | $34 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,419 | $1,417 | $1,416 | $1,410 |
| Retained Earnings | -$1,376 | -$1,369 | -$1,371 | -$1,347 |
| AOCI | -$48 | -$48 | -$48 | -$48 |
| Other Equity | $83 | $83 | $82 | $82 |
| Total Equity | $77 | $83 | $79 | $97 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $98 | $103 | $117 | $132 |
| Net Debt | -$21 | -$36 | -$36 | -$35 |